Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

1.200 +0.040 (+3.45%)
Streaming Delayed Price Updated: 9:54 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kairos Pharma, Ltd. Common Stock

< Previous 1 2 3 4 Next >
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2024 Milestones and 2025 Clinical Outlook
Via Investor Brand Network
Topics Intellectual Property
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why
Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves. 
Via Stocktwits
Kairos Pharma Provides Business Update and Outlook into 2025
From Kairos Pharma, Ltd
Via Business Wire
US Stocks Mixed; Nasdaq Down Over 1%
 
Via Benzinga
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Present at Lytham Partners Investor Healthcare Summit
Via Investor Brand Network
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – EF Hutton Provided ‘Buy’ Rating, $9.00 Price Target in Kairos Pharma, Ltd. (NYSE: KAPA) Recent Research Report
Via Investor Brand Network
BioMedNewsBreaks — Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
Via Investor Brand Network
Kairos Pharma to Participate in The Microcap Conference in January 2025
Via ACCESSWIRE
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Growth Strategy at The Microcap Conference 2025
Via Investor Brand Network
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Expands Phase 2 Trial of ENV105 to City of Hope for Prostate Cancer Therapy
Via Investor Brand Network
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Engages IBN for Corporate Communications Expertise
Via Investor Brand Network
Topics Intellectual Property
Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression
Via Investor Brand Network
Topics Intellectual Property
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
InvestorNewsBreaks – Kairos Pharma Ltd. (KAPA) to Dual List Shares on Upstream, Expanding Global Investor Access
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges
Via AB Newswire
Topics Initial Public Offering
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges 
Via News Direct
Topics Initial Public Offering
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.